TABLE 2.

Therapeutics working on multiple targets

Target	Specific effect/target molecule(s)	Intervention(s)	Status of SARS‐CoV‐2 trial	Sponsor/collaborators	NCT number
Combined intervention	3CLpro, interferon receptor (IFNAR)	†1 Lopinavir/ritonavir †2 Ribavirin †3 Interferon Beta‐1B	Phase 2	The University of Hong Kong, Hospital Authority, Hong Kong	NCT04276688
	3CLpro, interferon receptor (IFNAR)	†1 Xiyanping injection †2 Lopinavir/ritonavir, alpha‐interferon nebulization	Not applicable	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	NCT04275388
	ACE2 and spike binding complex, Endosomal acidification	†1 Azithromycin †2 Chloroquine	Phase 3	Population Health Research Institute	NCT04324463
	ACE2 and spike binding complex, Endosomal acidification	†1 Azithromycin †2 Hydroxychloroquine	Phase 4	Chronic Obstructive Pulmonary Disease Trial Network, Denmark	NCT04322396
	ACE2 and spike binding complex, Endosomal acidification	†1 Hydroxychloroquine + azithromycin †2 Hydroxychloroquine	Phase 3	Hospital Israelita Albert Einstein, EMS, Hospital do Coracao, Hospital Sirio‐Libanes, Brazilian Research In Intensive Care Network; Hospital do Coracao, Hospital Israelita Albert Einstein, Hospital Sirio‐Libanes, Brazilian Research In Intensive Care Network, EMS	NCT04321278, NCT04322123
	Endosomal acidification, RdRp	†1 Hydroxychloroquine †2 Remdesivir	Phase 2, Phase 3	Oslo University Hospital	NCT04321616
	Spike glycoprotein, 3CLpro	†1 Carrimycin †2 lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate	Phase 4	Beijing YouAn Hospital, Shenyang Tonglian Group Co., Ltd., Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences, Huangshi Central Hospital, Shenyang Pharmaceutical University, First Affiliated Hospital of Chongqing Medical University, The Second Affiliated Hospital of Harbin Medical University, No. 2 People's Hospital of Fuyang City, First Affiliated Hospital Bengbu Medical College, Renmin Hospital of Wuhan University, The Sixth People's Hospital of Shenyang, Nanyang Central Hospital	NCT04286503
	Spike glycoprotein, 3CLpro	†1 Abidol hydrochloride †2 Oseltamivir †3 Lopinavir/ritonavir	Phase 4	Tongji Hospital	NCT04255017

Note: †1, †2, and †3 are different arms of parallel intervention.